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Exhaled nitric oxide (NO) has been extensively investigated as a noninvasive marker of airway inflam­
ma  tion in asthma. The increased NO expression induced by inflammatory mediators in airways can 
be monitored easily in exhaled air from asthmatic children. Based on the relationship between the 
increased NO expression and eosinophilic airway inflammation, fractional exhaled nitric oxide (FeNO) 
measurements become an important adjunct for the evaluation of asthma. In addition, the availability 
of portable devices makes it possible to measure FeNO more easily and frequently in the routine 
pediatric practice. Despite various confounding factors affecting its levels, FeNO can be applicable in 
diagnosing asthma, monitoring treatment response, evaluating asthma control, and predicting asthma 
exacerbations. Thus, although pulmonary function tests are the standard tools for objective measure­
ments of asthmatic control, FeNO can broaden the way of asthma monitoring and supplement standard 
clinical asthma care guidelines. 
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Introduction
Although effective asthma control is achieved in the majority of asthmatic patients, a 
significant numbers of patients still suffer from frequent asthma aggravations which are 
usually related to airway inflammation
1,2). Moreover, patients whose asthma is considered 
under control still have evidences of airway inflammation
3). These findings imply that the 
routine assessment of airway inflammation is required to ensure the more successful 
management of asthma. However, treatment of asthma based on sufficient evidences of 
airway inflammation is not usually instigated even in tertiary referral centers. Instead, the 
managements of asthmatic patients are usually based on symptoms, pulmonary function 
tests, assessment of bronchodilator response, and bronchial challenge tests
4). However, 
symptoms or the results of basic pulmonary function tests may not reflect ongoing airway 
inflammation
5,6). For these reasons, the development of monitoring modalities to assess 
airway inflammation is mandatory. In addition, measurements should be easy to perform, 
reproducible, and associated with a high degree of acceptance by patients. 
Bronchoscopy with biopsy and induced sputum eosinophil count remain the best 
reliable tools for assessing airway inflammation. However, these monitoring methods 
are not always applicable as routine procedures because they are time consuming and 
accompanied by risks. More recently, fractional exhaled nitric oxide (FeNO) has been 
proposed as means of assessing airway inflammation. High FeNO values above certain 
cut-point may indicate active eosinophilic airway inflammation and the likelihood of 
deterioration in asthma control
7). FeNO measurements have also shown potential utility in 
guiding anti-inflammatory therapy in asthmatic patients
8-10). However, the clinical value 425 http://dx.doi.org/10.3345/kjp.2013.56.10.424
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of FeNO measurements may be questioned because FeNO levels 
are increased in asthma even in mild and asymptomatic condi-
tions
11,12). In addition, contribution of the possible sources of NO 
must be considered when exhaled NO is measured as a marker of 
airway inflammation. This review focuses on the basic features 
of exhaled NO and the role of FeNO measurements in pediatric 
asthma. 
Basic features of NO production
Nitric oxide (NO) had been considered to be an air pollutant 
without any specific biological roles. However, NO is involved 
in a broad range of physiologic and pathologic processes. NO is 
produced by a variety of cells including airway epithelial cells, 
vascular endothelial cells, and trafficking inflammatory cells. NO 
is usually synthesized by NO synthase (NOS) which catalyzes the 
oxidation of L-arginine to NO and L-citrulline
13) (Fig. 1). Neural 
NOS (NOS1), inducible NOS (iNOS, NOS2), and endothelial NOS 
(NOS3) are three different NOS isoenzymes
14). Constitutive NOS 
(cNOS) isoenzymes include NOS1 and NOS3, both of which 
are activated by calcium ions to produce small amounts of NO, 
which is presumed to play a local regulatory role, such as neuro-
transmission (NOS1) and regulation of local blood flow (NOS3)
15). 
In contrast to cNOS inducing NO production at picomolar 
con centrations for the transient period, iNOS is able to produce 
NO in nanomolar concentrations on a continuous basis
16), 
reflecting that iNOS is the most important isoenzyme in 
determining NO output. In addition, iNOS is not constitutively 
expressed but in duced by inflammatory or infectious stimuli and 
produces NO independent of calcium ion influx. The expression 
of iNOS is higher in the upper airways than in the lower ones 
and regulated at the transcriptional level
17). Expression of iNOS 
in respiratory epithelium has been shown to be upregulated by 
Th2 cytokines via the STAT-6 pathway
18). Asthmatic patients 
exhibit higher levels of iNOS mRNA expression than healthy 
controls. The expression of iNOS is decreased after the use 
of corticosteroid in patients with asthma. Close relationship 
between FeNO and epithelial iNOS mRNA expression supports 
that the increased expression of epithelial iNOS is responsible 
for high FeNO
19). 
Factors affecting FeNO levels
High FeNO is observed primarily in atopic asthma, which pre-
sents a contrast to normal or near-normal FeNO in nonatopic 
asthma
20). In addition, FeNO has been shown to be positively 
correlated with the level of IgE sensitization
21) and elevated 
after controlled or natural exposure to allergens
22). In this 
regard, inhaled allergens are probably the most important 
environmental agents enhancing FeNO levels particularly in 
atopic subjects. Previous studies have shown mixed results 
concerning interrelationship among asthma, atopy and FeNO. 
Some studies reported high FeNO mainly confined to atopic 
children independent of asthma status
23,24), while others have 
found higher FeNO levels in atopic subjects with concomitant 
asthma than those with atopy alone
20,25).
NO can be formed from nonenzymatic NOS-independent so-
urces via reduction of NO metabolites
26). Consumption of green 
vegetables with high amounts of nitrate can result in higher levels 
of NO in exhaled breath. The increase of exhaled NO seems to be 
proportional to the amount of ingested nitrate and last up to 15 
hours after intake
27). Therefore, it is required to instruct patients to 
avoid large amount of nitrate-rich food on the day of measure ment 
and encourage a mouthwash as this minimizes the effect of nitrate 
on FeNO. 
Although the results about the effect of physical exercise on 
FeNO are conflicting, it is better to refrain from physical exercise 
1 hour before FeNO measurements to minimize the effect of 
physical exercise
28). Cigarette smoking is associated with the 
reduced levels of FeNO, although FeNO is still high in smokers 
with asthma
26). Air pollution such as elevated levels of particulate 
matter or ozone is associated with the increase of FeNO both in 
healthy subjects and asthmatics
29,30). 
Rhinovirus (RV) infection has been known be a major cause of 
asthma exacerbation and appears to be associated with systemic 
eosinophilic activation leading to sputum eosinophilia. RV 
can induce iNOS expression in the airway epithelium resulting 
in enhanced NO production
31). NO response to RV infection 
is probably beneficial because NO suppress viral replication. 
Interestingly, asthmatic children with RV infection had lower 
FeNO than those without RV infection when their asthma was 
exacerbated
32), suggesting that RV infection is unlikely to be 
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Fig. 1. Nitric oxide synthetase (NOS)-dependent and -independent formation 
of nitric oxide (NO). iNOS, inducible NOS; cNOS, constitutive NOS.http://dx.doi.org/10.3345/kjp.2013.56.10.424
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involved in Th2-driven iNOS expression. 
Corticosteroids can reduce FeNO in asthmatic patients probably 
by inhibiting the activity of transcriptional factor GATA-3 which 
regulates interleukin (IL) 4/IL-13 expression in immune cells 
including Th2 lymphocytes
33). However, corticosteroids are not 
able to inhibit epithelial STAT-6 expression which is involved 
in iNOS expression
34). Because FeNO appears to be a marker for 
allergen-induced local airway inflammation, it can monitor the 
efficacy of different inhaled corticosteroids (ICS) preparations 
in the treatment of asthma. However, FeNO measurements 
may be less useful in monitoring asthmatic patients who are 
frequently exposure to specific allergens because FeNO remains 
high despite continuous use of ICS in these patients. Leukotriene 
receptor antagonists can reduce FeNO in asthmatic patients 
although this effect is less profound than corticosteroids
35). In 
contrast, theophylline and chromorines are not able to affect the 
level of FeNO
36,37). 
The levels of FeNO can be changed by bronchoconstriction 
and bronchodilation, implying a dependence of FeNO on airway 
caliber which is related to airway mucosal surface area for NO 
diffusion. Thus, continuous use of long-acting β2-agonist in 
asthmatic patients can result in increase of FeNO
38).
Despite inconsistent results concerning a sex difference in 
FeNO levels, there appears to be an association between female 
sex and lower levels of FeNO
26). This might be explained by lower 
endogenous NO production and smaller surface area of the con-
ductive airways in relation to body size in females. Height has 
been reported to be one of the most independent confounder for 
FeNO. In a previous study performed in children, an increase 
from 120 to 180 cm resulted in a doubling of exhaled NO levels, 
reflecting the greater airway mucosal surface area for NO diffusion 
as children grow
39). By the same token, increasing age is associ-
ated with an increase of exhaled NO in children. However, the 
influence of weight or body mass index on FeNO remains unclear 
because of mixed results in previous studies. Factors and their 
effects on FeNO are summarized in Table 1.
Methods of FeNO measurements
Exhaled NO is usually measured by chemiluminescence or 
electrochemical sensing. The chemiluminescence method was 
first used for detection of exhaled NO in the breath of humans 
and became the gold standard for FeNO measurements. However, 
the chemiluminescence-based NO analyzer is expensive and not 
portable. On the other hand, NO analyzers with electrochemical 
sensors are hand held devices and relatively cheaper than those 
based on chemiluminescence. Because there is a good agreement 
in FeNO levels between both devices, the use of hand held devices 
becomes increasing
40). 
After inhalation to total lung capacity, patients must exhale 
immediately into the NO analyzer until a steady plateau is reached. 
Because FeNO levels are flow dependent
41), exhalation should 
be stable at a targeted flow rate of 50 mL/sec and last for 6-10 
seconds. Higher exhalation flow rate as well as shorter exhalation 
time results in FeNO lower than true values. NO scrubber is 
usually used to ensure that the patients inhale NO-free air. 
According to the 2005 American Thoracic Society/European 
Respiratory Society guidelines
28), FeNO should be measured twice 
and a third measurement is required if there is a more than 10% 
difference between first two measurements. In addition, guidelines 
also recommend avoiding spirometric maneuver before FeNO 
measurements because this maneuver can lower FeNO. Thus, 
spirometry should be performed after FeNO measurements. Nasal 
clip should not be used as it can affect closure of the soft palate, 
leading to contamination with NO derived from the nasal 
cavity. In children younger than 5 years, single-breath online 
measurement is not well standardized since children cannot 
adequately cooperate. In very young children who cannot 
maintain a constant flow, FeNO levels are measured during spon-
taneous breathing, with the exhalation flow adjusted to 50 mL/
sec by changing the exhalation resistance
42).
Clinical application of FeNO in pediatric asthma
Based on its correlation with bronchial hyperresponsiveness
43), 
FeNO may be considered as a screening tool for asthma. Actually, 
sensitivity and specificity of FeNO measurements have been 
reported to be acceptable for the diagnosis of asthma in pre-
vious clinic-based studies
44,45). In particular, FeNO provides signi-
ficantly higher diagnostic accuracy than lung function tests in 
discriminating asthmatics from healthy subjects
44,46). The power 
of FeNO in diagnosing asthma can be increased further by the 
combination of airway hyperresponsiveness and elevated FeNO 
47). However, it is important to remember that low FeNO values 
do not exclude the diagnosis of asthma because FeNO levels are 
normal, especially in nonatopic subjects
7). In addition, because 
severity or phenotype of airway inflammation may be different 
Table 1. Factors affecting FeNO levels 
Factors increasing
FeNO Factors decreasing FeNO Factors with 
uncertain effect
Age Active smoking Passive smoking
Male Spirometric manoeuvres Exercise
Height Bronchial provocation Chromones
Atopy Corticosteroids Methylxanthines
Asthma Leukotriene receptor antagonist
Food (nitrate) Anti­IgE
FeNO, fractional exhaled nitric oxide.427 http://dx.doi.org/10.3345/kjp.2013.56.10.424
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among patients with atopic asthma, FeNO levels may be different 
among these patients
20). 
Prior publications have reported reference values for FeNO 
in healthy children and adolescents
48-50). However, because 
of multiple confounding factors influencing FeNO, normal 
predictive values for FeNO might be relatively poor and have 
large confidence intervals. According to the 2011 American 
Thoracic Society guideline for interpretation of FeNO for clinical 
applications
51), asthma with eosinophilic inflammation is less 
likely in children who have FeNO below 20 ppb. In contrast, FeNO 
levels higher than 35 ppb in children strongly suggest airway 
eosinophilia. Thus, discriminating asthma from nonasthmatic 
conditions in children with intermediate FeNO levels of 20-35 
ppb warrants cautious interpretations. For these children with 
symptoms suggesting asthma, the change of FeNO from the 
personal best FeNO value may be helpful in interpreting the level 
of airway inflammation because the intrasubject reproducibility 
of FeNO levels appears to be good
52). Based on currently available 
data, algorithms for interpretation and clinical application of 
FeNO results can be developed for diagnostic use and ongoing 
asthma management (Fig. 2). 
FeNO correlates with airway eosinophilia in induced sputum, 
biopsy material, and bronchoalveolar lavage fluid
53,54). There-
fore, FeNO measurements may be a useful monitoring tool for 
eosinophilic airway inflammation, without the practical difficulties 
associated with bronchial biopsy or sputum induction. Further-
more, high FeNO at the time of loss of asthma control
55,56) and 
decrease of FeNO after treatment with corticosteroids
57,58) imply 
that FeNO is useful not only in predicting asthma exacerbation 
but in monitoring the response to treatment. The changes in 
FeNO levels during use of inhaled and oral corticosteroids are 
rapid and reproducible when repeated
57). In this regard, FeNO 
measurements may be helpful in adjusting ICS dose in asthmatic 
individuals. However, because previous clinical trials reported 
only equivocal benefits of adding FeNO measurements to usual 
clinical guidelines for asthma management
8-10,59), it has not been 
determined that FeNO-based management is beneficial in routine 
clinical practice. In addition, despite the increase of FeNO prior 
to asthma exacerbation, evidences are not sufficient enough to 
suggest that FeNO measurements are able to role as a predictor 
of asthma exacerbation
60,61). Nevertheless, changes in FeNO levels 
from baseline and individually tailored FeNO values may be both 
good markers for the upcoming loss of asthma control
62). 
Although asthma aggravation is accompanied by increased 
symptoms, impaired lung function, and high FeNO levels, there 
may be discordance among these asthma outcomes. In particular, 
monitoring of asthma control based on symptoms and normal 
forced expiratory volume in 1 second might result in under-
treatment because persistent airway inflammation does not 
necessarily manifest itself as symptoms or lung malfunction
6,63). 
High FeNO levels in the absence of symptoms or lung function 
abnormalities raise the possibility of active eosinophilic airway 
inflammation and the likelihood of deterioration in asthma 
control. Thus, in cases of silent airway inflammation, monitoring 
with FeNO measurements might potentially allow for better 
targeting and monitoring of anti-inflammatory treatment
64). 
FeNO measurement 
FeNO > 35 ppb 
(EAI:significant) 
FeNO  20-35 ppb 
(EAI:equivocal) 
Symptoms 
Continuous allergen exposure 
Inadequate ICS dose or poor compliance 
Assess efficacy of management  + 
- 
Subclinical airway inflammation 
Monitor changes in FeNO 
No change in asthma management 
 
Symptoms 
Continuous allergen exposure 
Inadequate ICS dose or poor compliance 
Assess efficacy of management  + 
- 
High possibility of airway inflammation 
Possibility of relapse 
Monitor changes in FeNO 
 
FeNO  < 20 ppb 
(EAI*:unlikely) 
Symptoms 
Nonatopic asthma 
Neutrophilic asthma 
Nonasthmatic conditions  + 
- 
Controlled asthma 
Good compliance to medication 
Consider ICS tapering or withdrawal 
Fig. 2. Clinical application and interpretation of FeNO levels in pediatric asthma. FeNO, fractional exhaled nitric oxide; EAI, 
eosinophilic airway inflammation; ICS, inhaled corticosteroids.http://dx.doi.org/10.3345/kjp.2013.56.10.424
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However, further studies are required to elucidate whether sub-
clinical airway inflammation identified by FeNO measure  ments 
needs to be treated.
Conclusions
FeNO is a noninvasive surrogate marker of eosinophilic 
airway inflammation and responds rapidly to changes in 
the inflammatory state of the airways. Therefore, combined 
with other asthma outcomes, FeNO can provide additional 
information about the ongoing status of asthma. However, 
although FeNO measurements offer a step forward in the 
assessment of asthma, the interpretation of FeNO values in 
patients with asthma needs to be further clarified. Nevertheless, 
FeNO has a potential to serve as a tool for diagnosing and 
monitoring pediatric asthma.
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